Advertisement
News
Advertisement

Stealth Peptides enrolls first patient in Phase 2 study

Tue, 06/26/2012 - 5:31am
Mass High Tech: The Journal of New England Technology

Stealth Peptides Inc. of Newton Centre has enrolled the first of what it hopes to be 300 patients in its Phase 2 clinical trial to study the ability of its compound, Bendavia, to limit damage suffered in a heart attack.

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading